0QLQ Stock Chart & Stats
CHF401.80
CHF1.08(0.28%)
At close: 4:00 PM EDT
CHF401.80
CHF1.08(0.28%)
Day’s Range― - ―
52-Week RangeCHF263.50 - CHF417.00
Previous CloseN/A
Volume1.48K
Average Volume (3M)757.00
Market Cap
CHF5.18B
Enterprise ValueCHF3.97B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)24.2
Beta0.78
Next Earnings
Nov 11, 2026EPS Estimate
5.15Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,149,739
10 Day Avg. Volume372
30 Day Avg. Volume757
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF432.33Price Target Upside7.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.11
Revenue Forecast (FY)CHF700.63M
Bulls Say, Bears Say
Bulls Say
Core Business GrowthThe core Delivery Systems business is growing rapidly and management expects another year of double-digit expansion. This supports durable demand for Ypsomed’s devices and services, while the scale of the platform can improve operating leverage and reinforce its position with pharmaceutical customers.
Innovation And PipelineA broad product pipeline and new recyclable platforms can extend Ypsomed’s competitive relevance across injection and delivery applications. Management expects the platforms to extend IP protection into the 2030s and 2040s, supporting longer-lived customer relationships and future commercialization opportunities.
Profitability And Balance SheetStrong profitability combined with moderate leverage gives Ypsomed financial capacity to fund growth investments without relying excessively on debt. A 33% EBIT margin and net debt/EBITDA near 0.8 also provide resilience while new production capacity is brought online.
Bears Say
Recent Revenue ContractionThe latest top-line contraction shows that Ypsomed’s strong longer-term expansion is not yet consistent across all activities. If revenue weakness persists, it could reduce operating leverage, complicate capacity absorption, and make the company more dependent on continued growth in Delivery Systems.
Persistent Free Cash Flow DeficitNegative free cash flow despite strong operating cash generation indicates that investment or working-capital needs continue to absorb internally generated funds. Sustained cash conversion pressure could limit capital-allocation flexibility and increase reliance on successful capacity ramp-ups to earn back investment.
Transition And Ramp-up CostsThe shift away from contract manufacturing and simultaneous expansion of multiple sites may create a period of lower reported revenue and temporary underutilization. Ramp-up and stranded costs could weigh on margins before the new footprint reaches efficient production levels.
0QLQ FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest share price was CHF263.50 and its highest was CHF417.00 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.18B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 10 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.11%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.15.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,149,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in GB:0QLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
0QLQ Stock 12 Month Forecast
Average Price Target
CHF432.33
▲(7.60% Upside)
Technical Analysis
Lonza Group Ltd
―
DKSH Holding AG
―
medmix AG
―
Roche Holding Ltd
―
Lepu Medical Technology (Beijing) Co., Ltd. Sponsored Global Depositary Receipt Repr Sh -A- Reg S
―



